Drug intelligence / Profile preview

GS-2829

Development stage: Phase 1
Lead developer: Gilead Sciences
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GS-2829 is an investigational, nonreplicating arenaviral vector therapeutic vaccine based on the Pichinde virus (PICV). Developed by Gilead Sciences in collaboration with HOOKIPA Pharma, it is designed for the treatment of chronic hepatitis B (CHB). The vaccine encodes three highly conserved hepatitis B virus (HBV) antigens: core, surface antigen (HBsAg), and polymerase. GS-2829 is utilized in a heterologous prime-boost immunization strategy in combination with GS-6779 (a lymphocytic choriomeningitis virus-based vector). This approach aims to induce robust HBV-specific CD8+ T cell responses and high anti-HBs antibody titers to achieve a functional cure for HBV. It is currently being evaluated in Phase 1 clinical trials for safety, tolerability, and immunogenicity.

Other names: PICV-HBV vaccinePichinde virus-based HBV vaccine

Targets

HBV antigens (Hepatitis B virus antigens)

Beyond the preview

Go deeper on GS-2829.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-2829.

Explore the full profile